

Jack A Schalken

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1568922/jack-a-schalken-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

401
papers

18,898
citations

71
h-index

124
g-index

474
ext. papers

20,716
ext. citations

5.3
avg, IF

6.33
L-index

#	Paper	IF	Citations
401	DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. <i>Cancer Research</i> , 1999 , 59, 5975-9	10.1	710
400	Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. <i>Nature Genetics</i> , 2009 , 41, 221-7	36.3	509
399	DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. <i>European Urology</i> , 2003 , 44, 8-15; discussion 15-6	10.2	498
398	DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. <i>Cancer Research</i> , 2002 , 62, 2695-8	10.1	426
397	Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. <i>Cancer Research</i> , 1992 , 52, 5104-9	10.1	406
396	Allelic loss of chromosomes 16q and 10q in human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 8751-5	11.5	404
395	Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. <i>Cancer Research</i> , 1994 , 54, 3929-33	10.1	350
394	Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. <i>European Urology</i> , 2008 , 54, 1081-8	10.2	325
393	Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 35-63	1.6	314
392	Androgen receptors in endocrine-therapy-resistant human prostate cancer. <i>International Journal of Cancer</i> , 1991 , 48, 189-93	7.5	312
391	Cadherin switching in human prostate cancer progression. <i>Cancer Research</i> , 2000 , 60, 3650-4	10.1	283
390	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. <i>European Urology</i> , 2009 , 56, 275-86	10.2	279
389	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014 , 15, e484-92	21.7	277
388	Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 5103-8	12.9	273
387	Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. <i>European Urology</i> , 2014 , 65, 534-42	10.2	261
386	Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. <i>Cancer Research</i> , 1993 , 53, 3241-5	10.1	237
385	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015 , 26, 1589-604	10.3	220

384	Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. <i>European Urology</i> , 2016 , 70, 740-748	10.2	215
383	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
382	PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. <i>Journal of Immunotherapy</i> , 2012 , 35, 169-78	5	203
381	TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. <i>Cancer Research</i> , 2006 , 66, 10242-6	10.1	188
380	MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. <i>Oncogene</i> , 2013 , 32, 277-85	9.2	183
379	The use of PCA3 in the diagnosis of prostate cancer. <i>Nature Reviews Urology</i> , 2009 , 6, 255-61	5.5	166
378	Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3061-70	12.9	155
377	The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. <i>Clinical Cancer Research</i> , 2007 , 13, 939-43	12.9	153
376	Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. <i>Oncogene</i> , 2004 , 23, 5624-31	9.2	151
375	Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. <i>Cancer Research</i> , 1996 , 56, 4154-8	10.1	144
374	Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. <i>Urology</i> , 2005 , 66, 64-74	1.6	143
373	Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. <i>Prostate</i> , 1988 , 13, 25-38	4.2	143
372	Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. <i>European Urology</i> , 2009 , 56, 659-67	10.2	142
371	Canine prostate carcinoma: epidemiological evidence of an increased risk in castrated dogs. <i>Molecular and Cellular Endocrinology</i> , 2002 , 197, 251-5	4.4	139
370	Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. <i>Journal of Pathology</i> , 1996 , 180, 295-9	9.4	137
369	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015 , 68, 1033-44	10.2	136
368	Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. <i>American Journal of Pathology</i> , 2003 , 162, 1529-37	5.8	136
367	Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. <i>Cancer Research</i> , 1992 , 52, 6182-7	10.1	136

366	Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. <i>Laboratory Investigation</i> , 2000 , 80, 1251-8	5.9	133
365	fur gene expression as a discriminating marker for small cell and nonsmall cell lung carcinomas. <i>Journal of Clinical Investigation</i> , 1987 , 80, 1545-9	15.9	132
364	Molecular genetics and epidemiology of prostate carcinoma. <i>Endocrine Reviews</i> , 1999 , 20, 22-45	27.2	130
363	Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. <i>Prostate</i> , 2010 , 70, 10-6	4.2	128
362	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , 2010 , 2, 62ra92	17.5	125
361	Cellular and molecular biology of the prostate: stem cell biology. <i>Urology</i> , 2003 , 62, 11-20	1.6	123
360	Decreased expression of E-cadherin in the progression of rat prostatic cancer. <i>Cancer Research</i> , 1992 , 52, 2916-22	10.1	122
359	Genomic Markers in Prostate Cancer Decision Making. <i>European Urology</i> , 2018 , 73, 572-582	10.2	122
358	Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. <i>European Urology</i> , 2011 , 60, 1045-54	10.2	119
357	Role of E boxes in the repression of E-cadherin expression. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 241, 453-8	3.4	118
356	New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. <i>Urology</i> , 2003 , 62, 34-43	1.6	116
355	Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1987 , 84, 2421-5	11.5	114
354	Complex cadherin expression in human prostate cancer cells. <i>International Journal of Cancer</i> , 2000 , 85, 446-450	7.5	112
353	The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. <i>European Urology</i> , 2001 , 39, 390-9	10.2	105
352	Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. <i>Journal of Urology</i> , 2012 , 187, 795-801	2.5	97
351	Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. <i>Cancer Research</i> , 1993 , 53, 5512-6	10.1	97
350	Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. <i>European Urology</i> , 2013 , 63, 201-9	10.2	96
349	Molecular cloning and characterization of the human E-cadherin cDNA. <i>Molecular Biology Reports</i> , 1993 , 17, 123-8	2.8	93

348	Clinical use of novel urine and blood based prostate cancer biomarkers: a review. <i>Clinical Biochemistry</i> , 2014 , 47, 889-96	3.5	91
347	Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. <i>Molecular Medicine</i> , 2011 , 17, 657-64	6.2	88
346	Stem cell characteristics in prostate cancer cell lines. <i>European Urology</i> , 2010 , 57, 246-54	10.2	88
345	Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy. <i>Journal of Urology</i> , 1993 , 150, 2019-24	2.5	87
344	The role of genetic markers in the management of prostate cancer. <i>European Urology</i> , 2012 , 62, 577-87	10.2	86
343	Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. <i>BMC Cancer</i> , 2005 , 5, 57	4.8	86
342	Expression of basal cell keratins in human prostate cancer metastases and cell lines. <i>Journal of Pathology</i> , 2001 , 195, 563-70	9.4	85
341	Characterization of human c-fes/fps reveals a new transcription unit (fur) in the immediately upstream region of the proto-oncogene. <i>Molecular Biology Reports</i> , 1986 , 11, 117-25	2.8	85
340	Prostate cancer biomarker profiles in urinary sediments and exosomes. <i>Journal of Urology</i> , 2014 , 191, 1132-8	2.5	82
339	Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. <i>American Journal of Pathology</i> , 2011 , 178, 525-36	5.8	80
338	Identification of intermediate cell types by keratin expression in the developing human prostate. <i>Prostate</i> , 1998 , 34, 292-301	4.2	80
337	hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis. <i>Cancer Research</i> , 2006 , 66, 3531-40	10.1	79
336	Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2000 , 10, 153-9	2.8	77
335	Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. <i>Journal of Urology</i> , 2005 , 173, 1375-80	2.5	76
334	Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. <i>Cancer Research</i> , 1991 , 51, 606-11	10.1	76
333	Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions. <i>Prostate Cancer and Prostatic Diseases</i> , 2017 , 20, 12-19	6.2	75
332	In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. <i>Prostate</i> , 2009 , 69, 1683-93	4.2	73
331	Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: biological significance and clinical implications. <i>Cancer and Metastasis Reviews</i> , 1993 , 12, 29-37	9.6	73

330	Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. <i>International Journal of Cancer</i> , 1997 , 74, 374-7	7.5	71
329	Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. <i>Prostate</i> , 2008 , 68, 1215-22	4.2	71
328	The mechanoreceptor TRPV4 is localized in adherence junctions of the human bladder urothelium: a morphological study. <i>Journal of Urology</i> , 2011 , 186, 1121-7	2.5	70
327	Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. <i>Urology</i> , 2001 , 58, 367-71	1.6	70
326	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016 , 117, 215-25	5.6	66
325	Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 203, 1284-90	3.4	64
324	Noncoding RNAs as novel biomarkers in prostate cancer. <i>BioMed Research International</i> , 2014 , 2014, 591703	3	63
323	Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. <i>Molecular Medicine</i> , 2013 , 18, 1449-55	6.2	62
322	Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. <i>Carcinogenesis</i> , 2009 , 30, 698-705	4.6	62
321	Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2000 , 87, 217-220	7.5	62
320	Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. <i>Urology</i> , 1998 , 51, 44-50	1.6	60
319	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMIC ACTIVITY IN THE HUMAN PROSTATE. <i>Journal of Urology</i> , 1999 , 161, 332-337	2.5	60
318	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology</i> , 2018 , 19, e696-e708	21.7	59
317	Urinary biomarkers for prostate cancer: a review. <i>Asian Journal of Andrology</i> , 2013 , 15, 333-9	2.8	58
316	A rabbit model to tissue engineer the bladder. <i>Biomaterials</i> , 2004 , 25, 1657-61	15.6	57
315	Evolutionary conserved close linkage of the c-fes/fps proto-oncogene and genetic sequences encoding a receptor-like protein. <i>EMBO Journal</i> , 1986 , 5, 2197-202	13	57
314	Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. <i>Prostate</i> , 2002 , 51, 98-107	4.2	56
313	Single-nucleotide polymorphism in the E-cadherin gene promoter modifies the risk of prostate cancer. <i>International Journal of Cancer</i> , 2002 , 100, 683-5	7.5	54

312	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1369-1380	6.2	54
311	Rapid microwave-stimulated fixation of entire prostatectomy specimens. Biomed-II MPC Study Group. <i>Journal of Pathology</i> , 1997 , 183, 369-75	9.4	53
310	Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 46 Suppl, S3-10	7	53
309	The transcription factor Net regulates the angiogenic switch. <i>Genes and Development</i> , 2003 , 17, 2283-97	12.6	53
308	The influence of high-energy shock waves on the development of metastases. <i>Ultrasound in Medicine and Biology</i> , 1996 , 22, 339-44	3.5	53
307	A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. <i>British Journal of Cancer</i> , 1996 , 74, 573-8	8.7	53
306	The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. <i>Prostate</i> , 2007 , 67, 1432-8	4.2	52
305	A five-gene expression signature to predict progression in T1G3 bladder cancer. <i>European Journal of Cancer</i> , 2016 , 64, 127-36	7.5	50
304	A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. <i>Prostate</i> , 2017 , 77, 1401-1407	4.2	49
303	The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. <i>BJU International</i> , 2010 , 106, 1143-7	5.6	49
302	Coordinate recruitment of E-cadherin and ALCAM to cell-cell contacts by alpha-catenin. <i>Biochemical and Biophysical Research Communications</i> , 2000 , 267, 870-4	3.4	49
301	Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. <i>BJU International</i> , 2001 , 88 Suppl 2, 35-42; discussion 49-50	5.6	48
300	Models for studying benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2000 , 3, 28-33	6.2	48
299	Molecular analysis of multifocal prostate cancer lesions. <i>Journal of Pathology</i> , 1999 , 188, 271-7	9.4	47
298	The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R3327 PAT-2 rat prostatic cancer cell-line. A potentiating effect on the in vitro cytotoxicity of vinblastin. <i>Urological Research</i> , 1989 , 17, 13-9		46
297	Smoothelin expression characteristics: development of a smooth muscle cell in vitro system and identification of a vascular variant. <i>Cell Structure and Function</i> , 1997 , 22, 65-72	2.2	46
296	In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities. <i>Journal of Urology</i> , 1990 , 144, 785-9	2.5	45
295	Molecular PCA3 diagnostics on prostatic fluid. <i>Prostate</i> , 2007 , 67, 881-7	4.2	44

294	The genes for the calcium-dependent cell adhesion molecules P- and E-cadherin are tandemly arranged in the human genome. <i>Biochemical and Biophysical Research Communications</i> , 1994 , 203, 1291-4	2.4	44
293	The structure of the human c-fes/fps proto-oncogene. <i>EMBO Journal</i> , 1985 , 4, 2897-903	13	43
292	Complex cadherin expression in renal cell carcinoma. <i>Cancer Research</i> , 1996 , 56, 3234-7	10.1	43
291	Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients. <i>Prostate</i> , 2011 , 71, 415-20	4.2	42
290	Applicability of biomarkers in the early diagnosis of prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2004 , 4, 513-26	3.8	42
289	Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study. <i>Prostate Cancer and Prostatic Diseases</i> , 2019 , 22, 101-109	6.2	41
288	Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. <i>Prostate</i> , 2013 , 73, 113-20	4.2	41
287	Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. <i>Prostate</i> , 2010 , 70, 70-8	4.2	41
286	Changes in cadherin-catenin complexes in the progression of human bladder carcinoma. <i>International Journal of Cancer</i> , 1999 , 82, 70-6	7.5	41
285	p53 mutations have no additional prognostic value over stage in bladder cancer. <i>British Journal of Cancer</i> , 1994 , 70, 496-500	8.7	41
284	Rabbit urethra replacement with a defined biomatrix or small intestinal submucosa. <i>European Urology</i> , 2003 , 44, 266-71	10.2	40
283	Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy. <i>Journal of Urology</i> , 2019 , 202, 256-263	2.5	40
282	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by Targeting and. <i>Cancer Research</i> , 2017 , 77, 2008-2017	10.1	39
281	Genetic marker polymorphisms on chromosome 8q24 and prostate cancer in the Dutch population: DG8S737 may not be the causative variant. <i>European Journal of Human Genetics</i> , 2011 , 19, 118-20	5.3	38
280	IS INCREASED CAG REPEAT LENGTH IN THE ANDROGEN RECEPTOR GENE A RISK FACTOR FOR MALE SUBFERTILITY?. <i>Journal of Urology</i> , 2002 , 167, 621-623	2.5	38
279	Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. <i>BJU International</i> , 2017 , 120, 659-665	5.6	37
278	The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. <i>Journal of Urology</i> , 2013 , 189, 336-42	2.5	37
277	Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. <i>Prostate</i> , 1997 , 32, 196-204	4.2	37

276	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives. <i>Prostate</i> , 1998 , 36, 62-73	4.2	37
275	Intravesical gemcitabine: a phase 1 and pharmacokinetic study. <i>European Urology</i> , 2004 , 45, 182-6	10.2	37
274	Cytotoxic effects of high energy shock waves in different in vitro models: influence of the experimental set-up. <i>Journal of Urology</i> , 1991 , 145, 171-5	2.5	37
273	Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. <i>Anticancer Research</i> , 2003 , 23, 3327-31	2.3	37
272	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. <i>BMC Genomics</i> , 2007 , 8, 84	4.5	36
271	Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder. <i>European Urology</i> , 2007 , 52, 1213-21	10.2	36
270	Molecular markers for prostate cancer. <i>Cancer Letters</i> , 2007 , 249, 5-13	9.9	36
269	Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. <i>European Urology</i> , 2005 , 48, 1031-41	10.2	36
268	Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas. <i>Journal of Urology</i> , 1994 , 151, 217-22	2.5	36
267	Quantitative light microscopy in urological oncology. <i>Journal of Urology</i> , 1992 , 148, 1-13	2.5	36
266	p16 mutations/deletions are not frequent events in prostate cancer. <i>British Journal of Cancer</i> , 1996 , 74, 120-2	8.7	35
265	Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 483-92	5.9	34
264	Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. <i>International Journal of Cancer</i> , 1997 , 74, 523-8	7.5	34
263	Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. <i>BJU International</i> , 2004 , 93 Suppl 1, 27-9	5.6	34
262	Introduction: prostate cancer: from basic science to clinical application?. <i>Urology</i> , 2003 , 62, 1-2	1.6	34
261	Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells. <i>Prostate</i> , 2000 , 44, 313-21	4.2	34
260	Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. <i>European Urology</i> , 1998 , 33, 387-91	10.2	34
259	Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. <i>Urology</i> , 1996 , 48, 357-64	1.6	34

258	The role of HOXC6 in prostate cancer development. <i>Prostate</i> , 2015 , 75, 1868-76	4.2	33
257	The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. <i>European Urology</i> , 2004 , 46, 670-4	10.2	33
256	JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areas. <i>Journal of Molecular Evolution</i> , 2002 , 55, 322-35	3.1	33
255	Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. <i>Molecular and Cellular Endocrinology</i> , 2002 , 197, 153-65	4.4	33
254	Differential regulation of human alpha1-adrenoceptor subtypes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1999 , 359, 439-46	3.4	33
253	Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. <i>Journal of Urology</i> , 2007 , 177, 80-3	2.5	32
252	Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. <i>European Journal of Cancer</i> , 2019 , 110, 62-70	7.5	31
251	Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients. <i>Prostate</i> , 2018 , 78, 336-342	4.2	31
250	Testosterone measurement in patients with prostate cancer. <i>European Urology</i> , 2010 , 58, 65-74	10.2	31
249	Tubulin tyrosine ligase like 12 links to prostate cancer through tubulin posttranslational modification and chromosome ploidy. <i>International Journal of Cancer</i> , 2010 , 127, 2542-53	7.5	31
248	The Bard BTA test: its mode of action, sensitivity and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. <i>European Urology</i> , 1998 , 34, 99-106	10.2	31
247	Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. <i>Ultrasound in Medicine and Biology</i> , 1991 , 17, 391-9	3.5	31
246	Urine cell-based DNA methylation classifier for monitoring bladder cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 71	7.7	30
245	Isolation and characterization of the promoter of the human prostate cancer-specific DD3 gene. <i>Journal of Biological Chemistry</i> , 2000 , 275, 37496-503	5.4	30
244	Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. <i>European Urology</i> , 2007 , 52, 464-8	10.2	29
243	The role of cell adhesion molecules and proteases in tumor invasion and metastasis. <i>World Journal of Urology</i> , 1996 , 14, 151-6	4	29
242	Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases. <i>American Journal of Pathology</i> , 1991 , 139, 1389-400	5.8	29
241	The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. <i>European Urology</i> , 2006 , 49, 839-45; discussion 845	10.2	28

240	Mammary growth hormone and tumorigenesis--lessons from the dog. <i>Veterinary Quarterly</i> , 1999 , 21, 111-5	8	28
239	H-ras expression, genetic instability, and acquisition of metastatic ability by rat prostatic cancer cells following v-H-ras oncogene transfection. <i>Prostate</i> , 1991 , 18, 163-72	4.2	28
238	Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity. <i>Cancer</i> , 1993 , 72, 2667-74	6.4	28
237	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , 2017 , 8, 50804-50813	3.3	27
236	Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. <i>Cancer Research</i> , 1988 , 48, 2042-6	10.1	27
235	Alterations in expression of cadherin-6 and E-cadherin during kidney development and in renal cell carcinoma. <i>European Urology</i> , 2000 , 38, 331-8	10.2	26
234	Structure and nucleotide sequence of the 5' region of the human and feline c-sis proto-oncogenes. <i>Nucleic Acids Research</i> , 1986 , 14, 765-78	20.1	26
233	Structure of the feline c-fes/fps proto-oncogene: genesis of a retroviral oncogene. <i>Journal of Virology</i> , 1987 , 61, 2009-16	6.6	26
232	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014 , 74, 1222-30	4.2	25
231	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog. <i>Prostate</i> , 2000 , 44, 40-8	4.2	25
230	Neural network-based digitized cell image diagnosis of bladder wash cytology. <i>Diagnostic Cytopathology</i> , 2000 , 23, 171-9	1.4	25
229	Expression and molecular characterization of the growth hormone receptor in canine mammary tissue and mammary tumors. <i>Endocrinology</i> , 1999 , 140, 5907-14	4.8	25
228	Recurrent gene fusions in prostate cancer: their clinical implications and uses. <i>Current Urology Reports</i> , 2013 , 14, 214-22	2.9	24
227	Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system. <i>Prostate</i> , 1989 , 14, 323-39	4.2	24
226	Intratumoral nuclear morphologic heterogeneity in prostate cancer. <i>Urology</i> , 1997 , 49, 652-7	1.6	23
225	Carotenoid and vitamin intake, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>Cancer Causes and Control</i> , 2008 , 19, 125-34	2.8	23
224	Genetic organization of the c-sis transcription unit. <i>Nucleic Acids Research</i> , 1987 , 15, 959-70	20.1	23
223	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 219-230	3.8	23

222	Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 241-6	6.2	22
221	Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. <i>Journal of Hypertension</i> , 2005 , 23, 1997-2004	1.9	22
220	A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. <i>Cancer Gene Therapy</i> , 2001 , 8, 927-35	5.4	22
219	Effects of high-energy shock waves combined with biological response modifiers or Adriamycin on a human kidney cancer xenograft. <i>Urological Research</i> , 1990 , 18, 419-24		22
218	Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. <i>Theranostics</i> , 2020 , 10, 2273-2283	12.1	21
217	Integrative genomic, transcriptomic, and RNAi analysis indicates a potential oncogenic role for FAM110B in castration-resistant prostate cancer. <i>Prostate</i> , 2012 , 72, 789-802	4.2	21
216	Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 11347-55	6.3	21
215	An integrated framework of personalized medicine: from individual genomes to participatory health care. <i>Croatian Medical Journal</i> , 2012 , 53, 301-3	1.6	21
214	Polymorphisms in the E-cadherin (CDH1) gene promoter and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2006 , 42, 3219-27	7.5	21
213	Cigarette smoking, von Hippel-Lindau gene mutations and sporadic renal cell carcinoma. <i>British Journal of Cancer</i> , 2006 , 95, 374-7	8.7	21
212	Site-specific familial aggregation of prostate cancer. <i>International Journal of Cancer</i> , 2004 , 109, 611-7	7.5	21
211	Proliferative activity and branching morphogenesis in the human prostate: a closer look at pre- and postnatal prostate growth. <i>Prostate</i> , 2001 , 49, 132-9	4.2	21
210	Molecular prognostic factors in bladder cancer. <i>World Journal of Urology</i> , 1994 , 12, 84-8	4	21
209	HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. <i>International Journal of Cancer</i> , 1991 , 48, 709-16	7.5	21
208	Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer. <i>BJU International</i> , 2014 , 114, 608-16	5.6	20
207	Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. <i>Prostate</i> , 2009 , 69, 1624-34	4.2	20
206	Superficial and metachronous invasive bladder carcinomas are clonally related. <i>International Journal of Cancer</i> , 2001 , 93, 699-702	7.5	20
205	Mechanisms associated with abnormal E-cadherin immunoreactivity in human bladder tumors. <i>International Journal of Cancer</i> , 1999 , 83, 591-5	7.5	20

204	Liarozole, an antitumor drug, modulates cytokeratin expression in the Dunning AT-6sq prostatic carcinoma through in situ accumulation of all-trans-retinoic acid. <i>Prostate</i> , 1995 , 27, 129-40	4.2	20
203	Differential antiproliferative activities of alpha- and gamma-interferon and tumor necrosis factor alone or in combinations against two prostate cancer xenografts transplanted in nude mice. <i>Prostate</i> , 1991 , 18, 331-44	4.2	20
202	Differential expression of vimentin in rat prostatic tumors. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 1254-9	3.4	20
201	The long and winding road to FDA approval of a novel prostate cancer test: our story. <i>Clinical Chemistry</i> , 2013 , 59, 32-4	5.5	19
200	Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. <i>Prostate</i> , 2011 , 71, 1701-9	4.2	19
199	The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. <i>European Urology</i> , 2006 , 50, 76-82	10.2	19
198	Homozygous deletions of p16(INK4) occur frequently in bilharziasis-associated bladder cancer. <i>International Journal of Cancer</i> , 1996 , 68, 183-7	7.5	19
197	Early metabolic response to high energy shock waves in a human tumor kidney xenograft monitored by 31P magnetic resonance spectroscopy. <i>Ultrasound in Medicine and Biology</i> , 1991 , 17, 791-801	7.5	19
196	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008 , 102, 177-82	5.6	18
195	Activated Leukocyte Cell Adhesion Molecule (ALCAM) Expression is Associated with a Poor Prognosis for Bladder Cancer Patients. <i>UroOncology</i> , 2003 , 3, 121-129		18
194	Canine balloon and signet-ring cell melanomas: a histological and immunohistochemical characterization. <i>Journal of Comparative Pathology</i> , 2001 , 125, 166-73	1	18
193	Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients. <i>International Journal of Cancer</i> , 2020 , 146, 3196-3206	7.5	18
192	Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation. <i>Advanced Science</i> , 2020 , 7, 2001797	13.6	18
191	A Four-Group Urine Risk Classifier for Predicting Outcome in Prostate Cancer Patients. <i>BJU International</i> , 2019 , 124, 609	5.6	17
190	Expression of periglandular tenascin-C and basement membrane laminin in normal prostate, benign prostatic hyperplasia and prostate carcinoma. <i>BJU International</i> , 1998 , 81, 844-51	5.6	17
189	The prognostic value of E-cadherin, alpha-, beta- and gamma-catenin in bladder cancer patients who underwent radical cystectomy. <i>International Journal of Urology</i> , 2007 , 14, 789-94	2.3	17
188	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. <i>Journal of Endocrinology</i> , 2002 , 172, 489-95	4.7	17
187	Differential sensitivity of renal cell carcinoma xenografts towards therapy with interferon-alpha, interferon-gamma, tumor necrosis factor and their combinations. <i>Urological Research</i> , 1991 , 19, 91-8		17

186	Tubulin tyrosine ligase like 12, a TTL family member with SET- and TTL-like domains and roles in histone and tubulin modifications and mitosis. <i>PLoS ONE</i> , 2012 , 7, e51258	3.7	17
185	Establishment and characterization of five new human renal tumor xenografts. <i>American Journal of Pathology</i> , 1992 , 140, 483-95	5.8	17
184	Urothelium update: how the bladder mucosa measures bladder filling. <i>Acta Physiologica</i> , 2017 , 220, 201-217	3.67	16
183	Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. <i>Prostate International</i> , 2014 , 2, 105-13	3.4	16
182	Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. <i>BJU International</i> , 2004 , 93 Suppl 1, 5-9	5.6	16
181	Comparative analysis of the human and feline c-sis proto-oncogenes. Identification of 5' human c-sis coding sequences that are not homologous to the transforming gene of simian sarcoma virus. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985 , 825, 140-7		16
180	Conventional bladder wash cytology performed by four experts versus quantitative image analysis. <i>Modern Pathology</i> , 1997 , 10, 976-82	9.8	16
179	Molecular biomarkers to guide precision medicine in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017 , 17, 791-804	3.8	15
178	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017 , 31, e3986	1.7	15
177	An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. <i>Prostate</i> , 2010 , 70, 1524-32	4.2	15
176	Tenascin expression in normal, hyperplastic, dysplastic and neoplastic canine mammary tissues. <i>Journal of Comparative Pathology</i> , 2002 , 126, 1-8	1	15
175	Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. <i>Oncogene</i> , 2019 , 38, 3696-3709	9.2	14
174	Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation. <i>Journal of Urology</i> , 2015 , 193, 1023-9	2.5	14
173	New perspectives in the treatment of prostate cancer. <i>European Urology</i> , 1997 , 31 Suppl 2, 20-3	10.2	14
172	Engineered FGF-2 expression induces glandular epithelial hyperplasia in the murine prostatic dorsal lobe. <i>European Urology</i> , 2004 , 46, 126-32	10.2	14
171	Critical review of the models to study the biologic progression of bladder cancer. <i>Journal of Surgical Oncology</i> , 1992 , 8, 274-8		14
170	Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. <i>Invasion & Metastasis</i> , 1994 , 14, 71-81		14
169	Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. <i>BJU International</i> , 2017 , 119, 74-81	5.6	13

168	TRPV4 channels in the human urogenital tract play a role in cell junction formation and epithelial barrier. <i>Acta Physiologica</i> , 2016 , 218, 38-48	5.6	13
167	Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. <i>European Urology Supplements</i> , 2010 , 9, 675-691	0.9	13
166	Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. <i>Prostate</i> , 1997 , 31, 14-20	4.2	13
165	Molecular prostate cancer pathology: current issues and achievements. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 82-93		13
164	Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt. <i>Urology</i> , 2000 , 55, 363-7	1.6	13
163	Immune response in hormonally-induced prostatic hyperplasia in the dog. <i>Veterinary Immunology and Immunopathology</i> , 2001 , 78, 297-303	2	13
162	A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 1999 , 2, 277-281	6.2	13
161	In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines. <i>Prostate</i> , 1995 , 26, 275-80	4.2	13
160	In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. <i>Journal of Urology</i> , 1990 , 143, 1247-51	2.5	13
159	A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate. <i>Oncotarget</i> , 2017 , 8, 10565-10579	3.3	13
158	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021 , 148, 385-395	7.5	13
157	Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. <i>Clinical Cancer Research</i> , 1996 , 2, 1055-61	12.9	13
156	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020 , 66, 842-851	5.5	12
155	Direct dynamic measurement of intracellular and extracellular lactate in small-volume cell suspensions with (13)C hyperpolarised NMR. <i>NMR in Biomedicine</i> , 2015 , 28, 1040-8	4.4	12
154	Identification and partial characterization of two steroid 5 alpha-reductase isozymes in the canine prostate. <i>Prostate</i> , 1998 , 34, 222-30	4.2	12
153	Polymorphisms in the alpha1A-adrenoceptor gene do not modify the short- and long-term efficacy of alpha1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 2006 , 97, 852-5	5.6	12
152	Expression of the human fes cellular oncogene in renal cell tumors. <i>Urological Research</i> , 1986 , 14, 123-7		12
151	Characterization of the feline c-abl proto-oncogene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1985 , 824, 104-12		12

150	XRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in Mice. <i>PLoS ONE</i> , 2016 , 11, e0159531	3.7	12
149	Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 89, 102069	14.4	12
148	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019 , 30, e3	10.3	12
147	Involvement of orphan nuclear receptor COUP-TFII in cadherin-6 and cadherin-11 regulation: implications in development and cancer. <i>Mechanisms of Development</i> , 2015 , 136, 64-72	1.7	11
146	Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014 , 6, 245-52	3.2	11
145	Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. <i>European Urology</i> , 2003 , 44, 615-9	10.2	11
144	Allelic imbalance in hereditary and sporadic prostate cancer. <i>Prostate</i> , 2003 , 54, 50-7	4.2	11
143	Alcohol dehydrogenase type 3 (ADH3) and the risk of bladder cancer. <i>European Urology</i> , 2001 , 40, 509-14	10.2	11
142	Karyometry in recurrent superficial transitional cell tumors of the bladder. <i>Urological Research</i> , 1992 , 20, 375-81		11
141	The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. <i>Urological Research</i> , 1993 , 21, 413-21		11
140	The role of PCA3 testing in patients with a raised prostate-specific antigen level after Greenlight photoselective vaporization of the prostate. <i>Journal of Endourology</i> , 2010 , 24, 1821-4	2.7	10
139	The Androgen Cascade in Ageing Men: Blessing or Curse?. <i>European Urology Supplements</i> , 2003 , 2, 8-12	0.9	10
138	Growth hormone induces tyrosyl phosphorylation of the transcription factors Stat5a and Stat5b in CMT-U335 canine mammary tumor cells. <i>Domestic Animal Endocrinology</i> , 2001 , 20, 123-35	2.3	10
137	In vitro antiproliferative efficacy of interferon-alpha, -gamma and tumor necrosis factor on two human renal tumor xenografts. <i>Urological Research</i> , 1988 , 16, 309-14		10
136	Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. <i>Stem Cell Research and Therapy</i> , 2017 , 8, 95	8.3	9
135	Inflammation in the Pathophysiology of Benign Prostatic Hypertrophy. <i>European Urology Supplements</i> , 2015 , 14, e1455-e1458	0.9	9
134	DC-SCRIPT: AR and VDR regulator lost upon transformation of prostate epithelial cells. <i>Prostate</i> , 2012 , 72, 1708-17	4.2	9
133	Personalized management in low-risk prostate cancer: the role of biomarkers. <i>Prostate Cancer</i> , 2012 , 2012, 327104	1.9	9

132	Molecular aspects of hormone-independent prostate cancer. <i>BJU International</i> , 2007 , 100 Suppl 2, 52-5	5.6	9
131	Molecular Diagnostics in Prostate Cancer. <i>EAU Update Series</i> , 2005 , 3, 200-213		9
130	Validation of molecular targets in prostate cancer. <i>BJU International</i> , 2005 , 96 Suppl 2, 23-9	5.6	9
129	Identification of androgen-responsive genes that are alternatively regulated in androgen-dependent and androgen-independent rat prostate tumors. <i>Genes Chromosomes and Cancer</i> , 2005 , 43, 273-83	5	9
128	Partial sequencing and tissue distribution of the canine isoforms of steroid 5alpha-reductase type I and type II. <i>Prostate</i> , 2000 , 44, 233-9	4.2	9
127	Branching activity in the human prostate: a closer look at the structure of small glandular buds. <i>European Urology</i> , 2001 , 39, 222-31	10.2	9
126	Oncogene expression in prostate cancer. <i>World Journal of Urology</i> , 1991 , 9, 58-63	4	9
125	Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis. <i>Cancers</i> , 2020 , 12,	6.6	8
124	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 222-229	3.2	8
123	PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis. <i>Cancers</i> , 2010 , 2, 1432-40	6.6	8
122	Differential expression of ferritin heavy chain in a rat transitional cell carcinoma progression model. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1997 , 1360, 39-44	6.9	8
121	Alcohol consumption and mutations or promoter hypermethylation of the von Hippel-Lindau gene in renal cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 3543-50	4	8
120	Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. <i>Urology</i> , 2002 , 60, 357-62	1.6	8
119	Consecutive quantitative cytology in bladder cancer. <i>Urology</i> , 2000 , 56, 584-8	1.6	8
118	Comparative analysis of p53 mutations in bladder washings and histologic specimens. <i>American Journal of Clinical Pathology</i> , 1998 , 110, 647-52	1.9	8
117	Loss of chromosome 9 in tissue sections of transitional cell carcinomas as detected by interphase cytogenetics. A comparison with RFLP analysis. <i>Journal of Pathology</i> , 1996 , 179, 169-76	9.4	8
116	Antitumor effects of bacillus Calmette-Guerin in a syngeneic rat bladder tumor model system, RBT323. <i>Journal of Urology</i> , 1993 , 149, 179-82	2.5	8
115	Magnetic resonance spectroscopy detects metabolic differences between seven Dunning rat prostate tumor sublines with different biological behavior. <i>Prostate</i> , 1994 , 25, 19-28	4.2	8

114	Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 1110-1119	6.2	8
113	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 202.e19-28	2.8	7
112	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020 , 17, 351-362	5.5	7
111	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer.. <i>JCO Precision Oncology</i> , 2020 , 4, 714-729	3.6	7
110	MULTIFOCAL TRANSITIONAL CELL CANCER AND p53 MUTATION ANALYSIS. <i>Journal of Urology</i> , 1998 , 160, 124-125	2.5	7
109	Future opportunities for the diagnosis and treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2004 , 7 Suppl 1, S8-S13	6.2	7
108	Lower incidence of urothelial cell carcinoma due to the concept of a clonal origin. <i>European Journal of Cancer</i> , 2000 , 36, 2385-9	7.5	7
107	The effects of successive high-energy shock-wave tumor administration on tumor blood flow. <i>Ultrasound in Medicine and Biology</i> , 1995 , 21, 243-8	3.5	7
106	Biological effects of high energy shock waves in mouse skeletal muscle: correlation between 31P magnetic resonance spectroscopic and microscopic alterations. <i>Ultrasound in Medicine and Biology</i> , 1993 , 19, 399-409	3.5	7
105	Liquid biopsy in bladder cancer: State of the art and future perspectives.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 170, 103577	7	7
104	TRPV4 mediates afferent pathways in the urinary bladder. A spinal c-fos study showing TRPV1 related adaptations in the TRPV4 knockout mouse. <i>Pflugers Archiv European Journal of Physiology</i> , 2016 , 468, 1741-9	4.6	7
103	Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis. <i>Cancers</i> , 2021 , 13,	6.6	7
102	Validation of a 2-gene mRNA urine test for the detection of α KG2 prostate cancer in an opportunistic screening population. <i>Prostate</i> , 2020 , 80, 500-507	4.2	6
101	The Role of Biomarkers and Genetics in the Diagnosis of Prostate Cancer. <i>European Urology Focus</i> , 2015 , 1, 99-108	5.1	6
100	High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. <i>BJU International</i> , 2013 , 111, 836-42	5.6	6
99	Androgen Receptor Mediated Growth of Prostate (Cancer). <i>European Urology Supplements</i> , 2005 , 4, 4-110.9	6	6
98	CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomas. <i>International Journal of Cancer</i> , 2005 , 116, 282-4	7.5	6
97	DETECTION OF ABNORMAL E-CADHERIN EXPRESSION BY SIMULATED PROSTATE BIOPSY. <i>Journal of Urology</i> , 1998 , 160, 1368-1372	2.5	6

96	Inhibition of rat bladder tumor (RBT323) growth by tumor necrosis factor alpha and interferon-gamma in vivo. <i>Journal of Urology</i> , 1992 , 148, 458-62	2.5	6
95	Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene. <i>Gene</i> , 1985 , 35, 33-43	3.8	6
94	Image analysis in superficial transitional cell carcinoma of the bladder. <i>Seminars in Urology</i> , 1993 , 11, 164-70		6
93	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS 1996 , 180, 295		6
92	A new, straightforward ex vivo organoid bladder mucosal model for preclinical research. <i>Journal of Urology</i> , 2013 , 190, 341-9	2.5	5
91	Analytical validation of an mRNA-based urine test to predict the presence of high-grade prostate cancer. <i>Translational Medicine Communications</i> , 2017 , 2,	4	5
90	Prostate cancer susceptibility genes on 8p21-23 in a Dutch population. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 248-53	6.2	5
89	Quantitative cytology on bladder wash versus voided urine: a comparison of results. <i>European Urology</i> , 2006 , 49, 1044-9; discussion 1049-50	10.2	5
88	Role of complex cadherins in cell-cell adhesion evaluated by spheroid formation in renal cell carcinoma cell lines. <i>Oncology Reports</i> , 2004 , 11, 357	3.5	5
87	High energy shock waves induced increase in the local concentration of systemically given TNF-alpha. <i>Journal of Urology</i> , 1994 , 152, 2164-6	2.5	5
86	Effect of alpha- and gamma-interferon and tumor necrosis factor on colony formation of two human renal tumor xenografts in vitro. <i>Journal of Surgical Oncology</i> , 1988 , 4, 195-8		5
85	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 248-248	2.2	5
84	A Novel Immunoenzymatic Technique to Demonstrate Multiple Antigens in Cells Based on Selective Destaining of Substrate Deposits and Its Application in Characterizing the Immunophenotype of Neuroendocrine Cells in the Human Prostate Epithelium. <i>Applied Immunohistochemistry & Molecular Morphology</i> , 1998 , 6, 69-76		5
83	The need for a personalized approach for prostate cancer management. <i>BMC Medicine</i> , 2015 , 13, 109	11.4	4
82	An update of the interstitial cell compartment in the normal human bladder. <i>BioMed Research International</i> , 2014 , 2014, 464217	3	4
81	Transient tenascin enhancement is an early event after androgen ablation in rat prostate. <i>Urological Research</i> , 1999 , 27, 9-15		4
80	Effects of high energy shock waves on tumor blood flow and metabolism: 31P/1H/2H nuclear magnetic resonance study. <i>NMR in Biomedicine</i> , 1994 , 7, 319-26	4.4	4
79	How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. <i>Central European Journal of Urology</i> , 2012 , 65, 110-2	0.9	4

78	Improving the barrier function of damaged cultured urothelium using chondroitin sulfate. <i>Neurourology and Urodynamics</i> , 2020 , 39, 558-564	2.3	4
77	Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1- C]pyruvate MRS and [F]FDG-PET. <i>NMR in Biomedicine</i> , 2020 , 33, e4362	4.4	4
76	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021 , 15, 2453-2465	7.9	4
75	Predictive and Prognostic Biomarker Identification in a Large Cohort of Androgen Receptor-Positive Salivary Duct Carcinoma Patients Scheduled for Combined Androgen Blockade. <i>Cancers</i> , 2021 , 13,	6.6	4
74	Complex cadherin expression in human prostate cancer cells 2000 , 85, 446		4
73	Self-reported acne is not associated with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 941-5	2.8	3
72	Transmembrane protease serine 2 in prostate cancer. <i>BJU International</i> , 2010 , 105, 1490-2	5.6	3
71	IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA. <i>Journal of Urology</i> , 2008 , 179, 725-725	2.5	3
70	New Developments in the Pathobiology of Prostate Disease. <i>European Urology Supplements</i> , 2006 , 5, 729-736	0.9	3
69	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001 , 47, 14-20	4.2	3
68	Treatment options in hormone resistant prostate cancer. <i>Annals of Oncology</i> , 2002 , 13 Suppl 4, 95-102	10.3	3
67	Expression of proto-oncogenes in xenografts of human renal cell carcinomas. <i>Urological Research</i> , 1987 , 15, 349-53		3
66	Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2021 , 39, 3789-3797	4	3
65	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. <i>Annals of Oncology</i> , 2018 , 29, viii274	10.3	3
64	Alterations of the myovesical plexus of the human overactive detrusor. <i>BioMed Research International</i> , 2014 , 2014, 754596	3	2
63	2104 PROSPECTIVE MULTICENTER EVALUATION OF PCA3 AND TMPRSS2-ERG GENE FUSIONS AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2012 , 187,	2.5	2
62	Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time. <i>European Urology Supplements</i> , 2009 , 8, 97-102	0.9	2
61	Molecular cloning of an alternative human alphaE-catenin cDNA. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 237, 177-81	3.4	2

60	Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. <i>European Urology</i> , 2008 , 54, 1438-9	10.2	2
59	Cadherin Switching in Human Prostate Cancer Progression. <i>Japanese Journal of Urology</i> , 2000 , 91, 92		2
58	Use of animal models in diagnosis and treatment of renal cell carcinoma. <i>World Journal of Urology</i> , 1991 , 9, 192-197	4	2
57	Increased expression of retroviral sequences in progressionally advanced rat prostatic tumors. <i>Biochemical and Biophysical Research Communications</i> , 1992 , 182, 318-24	3.4	2
56	Synergistische antiproliferative Wirkungen des rekombinanten Ratten-Gamma-Interferon und des humanen Tumor Nekrose Faktor Alpha in einem Rattennierenzellkarzinom-Modell. <i>Aktuelle Urologie</i> , 1990 , 21, 109-115	0.4	2
55	Oncogenes and urological malignancies: implications for the future. <i>Urological Research</i> , 1988 , 16, 333-9		2
54	Oncogene expression in prostate cancer. <i>Progress in Clinical and Biological Research</i> , 1990 , 357, 97-105		2
53	In Vitro Sensitivity of Three Human Renal Tumor Xenografts Towards Tumor Necrosis Factor and Alpha and Gamma Interferon 1989 , 30-38		2
52	Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice. <i>Urology Practice</i> , 2019 , 6, 256-261	0.8	2
51	Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. <i>Oral Oncology</i> , 2020 , 110, 105018	4.4	2
50	Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder. <i>Molecular Oncology</i> , 2021 , 15, 1882-1900	7.9	2
49	Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2024357119	11.5	2
48	Adherence junctions and cadherin-11 in normal and overactive human detrusor smooth muscle cells. <i>Journal of Urology</i> , 2011 , 185, 1946-51	2.5	1
47	1036 THE UROTHELIAL CELL-LINE RT4 EXPRESSES A GLYCOSAMINOGLYCAN (GAG) LAYER ON ITS OUTER SURFACE; AN IN VITRO MODEL FOR THE BLADDER GAG-LAYER. <i>Journal of Urology</i> , 2010 , 183,	2.5	1
46	Editorial comment on: Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. <i>European Urology</i> , 2007 , 52, 1679	10.2	1
45	Prostate (Cancer) Stem Cells 2007 , 63-72		1
44	Etiology and management of pelvic pain syndrome. <i>Urology</i> , 2004 , 63, 74	1.6	1
43	Image analysis and grading of prostate adenocarcinoma. <i>World Journal of Urology</i> , 1991 , 9, 86-94	4	1

42	Identification of new prostate cancer progression markers by differential hybridization analysis. <i>European Urology</i> , 1992 , 21 Suppl 1, 60-5	10.2	1
41	Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. <i>Progress in Clinical and Biological Research</i> , 1992 , 378, 9-18		1
40	Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. <i>Analytical Cellular Pathology</i> , 1994 , 7, 153-70		1
39	Development and validation of a bioanalytical assay on LC/MS/MS to quantify enzalutamide and N-desmethylenzalutamide in human plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 330-330	2.2	1
38	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5036-5036	2.2	1
37	PCA3 2009 , 233-241		1
36	Elevated HOXC6/DLX1 mRNA biomarker levels in urine to help select patients at increased risk for high-grade prostate cancer detection upon prostate biopsy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 31-31 ^{2.2}	2.2	1
35	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	1
34	Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports. <i>BMC Urology</i> , 2019 , 19, 124	2.2	1
33	HISTOLOGICAL GRADE HETEROGENEITY IN MULTIFOCAL PROSTATE CANCER. BIOLOGICAL AND CLINICAL IMPLICATIONS 1996 , 180, 295		1
32	Cell kinetics of prostate exocrine and neuroendocrine epithelium and their differential interrelationship: New perspectives 1998 , 36, 62		1
31	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.. <i>Cancers</i> , 2021 , 13,	6.6	1
30	Reply to Juan Morote Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010 , 57, e2-e3	10.2	0
29	Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007. <i>European Urology Supplements</i> , 2008 , 7, 460-476	0.9	0
28	Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 91-91	2.2	0
27	The importance of targeting intracrinology in prostate cancer management. <i>World Journal of Urology</i> , 2019 , 37, 751-757	4	0
26	Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 721659	5.3	0
25	Cell kinetics and differentiation after hormonal-induced prostatic hyperplasia in the dog 2000 , 44, 40		0

- 24 Biomarkers for Prostate Cancer **2017**, 77-96
- 23 Validatie van een nieuwe urinetest voor klinisch significante prostaatkanker. *Tijdschrift Voor Urologie*, **2016**, 6, 34-43 0.2
- 22 Next Generation Screening Tests **2013**, 347-354
- 21 Contemporary approaches to prostate cancer management. *Future Oncology*, **2015**, 11, 2735-6 3.6
- 20 Editorial comment on: Mutations in the AXIN1 gene in advanced prostate cancer. *European Urology*, **2009**, 56, 494 10.2
- 19 Reply to the letter to the editor: Differential expression of PCA3 and BMCC1 in Prostate Cancer,[] by Lavin M.F., Clarke R. and R.A. Gardiner. *Prostate*, **2009**, 69, 1715-1715 4.2
- 18 Personalized cancer therapy for urological cancers: from bench to bedside and back. *Advances in Urology*, **2012**, 2012, 298105 1.6
- 17 Reply to Tomasz Drewa's Letter to the Editor re: Minja J. Pfeiffer, Jack A. Schalken. Stem Cell Characteristics in Prostate Cancer Cell Lines. *Eur Urol* 2010;57:246B5. *European Urology*, **2010**, 57, e27 10.2
- 16 Genetic and molecular markers in the prognosis of bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **1998**, 4, 139-44 2.8
- 15 Basic research. *International Journal of Urology*, **1995**, 2 Suppl 2, 117-21 2.3
- 14 Prognostic Factors in Prostate Cancer **1996**, 77-85
- 13 Cell Adhesion Molecules in Genitourinary Cancer **2003**, 455-472
- 12 Interferon and Tumor Necrosis Factor in Renal Cell Carcinoma Model Systems **1991**, 47-55
- 11 Antitumor Effects of High-Energy Shock Waves are Potentiated by Doxorubicin and Biological Response Modifiers **1991**, 228-237
- 10 Prediction of Cytokine-Therapy on Basis of Class-I and Class-II MHC Antigen Induction **1992**, 121-133
- 9 Magnetic Resonance Spectroscopic Evaluation of the Effects of High-Energy Shock Waves Administered to a Human Kidney Cancer Xenograft **1993**, 34-39
- 8 Antitumorale Wirkungen immuntherapeutischer Agenzien in vitro und in vivo in einem syngenem Tiermodell des Nierenzellkarzinoms **1993**, 62-71
- 7 Genetische Schritte in Zusammenhang mit der Entstehung des Prostatakarzinoms **1993**, 151-165

6 Therapeutic Applications of Monoclonal Antibodies in Combination with Cytokines in Renal Cell Carcinoma **1994**, 132-140

5 Analytical challenges in quantitative analysis (LC/MS/MS) of abiraterone: A validated assay to determine abiraterone in human plasma.. *Journal of Clinical Oncology*, **2016**, 34, 329-329 2.2

4 Biomarkers for Prostate Cancer **2012**, 55-68

3 Molecular Identification of the Indolent Versus Lethal Tumor **2013**, 81-94

2 Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.. *Journal of Clinical Oncology*, **2021**, 39, 6071-6071 2.2

1 First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. *Journal of Clinical Oncology*, **2022**, 40, 40-40 2.2